Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMCODE003
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- NCT05968326 ↗
- Active, not recruiting
- Genentech, Inc.
- Focused
We haven't built an HCP commentary report on IMCODE003 (autogene cevumeran plus atezolizumab in resected pancreatic ductal adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMCODE003 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Adenocarcinoma, Pancreatic Ductal
- Interventions
- Autogene cevumeran; Atezolizumab; mFOLFIRINOX
- Arms
- Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX · Experimental
- Arm 2: mFOLFIRINOX · Active comparator
- Enrollment
- 260 (estimated)
- Primary outcomes
- Disease Free Survival (DFS)
- Sponsor
- Genentech, Inc. with BioNTech SE
- Start
- Oct 18, 2023
- Primary completion
- Jan 1, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05968326 · updated Sep 9, 2026